Advertisement

Topics

Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi

06:30 EST 10 Nov 2017 | Xconomy

Call it a week of second chances. Multiple biotechs breathed new life into drugs sorely in need of it. Sage Therapeutics proved a drug that had failed a trial a rare form of epilepsy could be the first ever approved therapy for postpartum depression. Otonomy, reviving a hearing loss drug thought to be on the […]

Original Article: Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi

NEXT ARTICLE

More From BioPortfolio on "Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...